A study about the impact of intensive instruction on the use of Aricept and the reasons for discontinuation in patients with Alzheimer's Disease
Not Applicable
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-UMIN000012617
- Lead Sponsor
- Shonan Fujisawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients treated with donepezil, galantamine, rivastigmine in 4 weeks immediately before enrollment 2) Known hypersensitivity to donepezil or piperadine derivatives 3) Involvement in any other investigational drug clinical trial during the preceding 12 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Medication persistence rate at 48 weeks Reasons for discontinuation
- Secondary Outcome Measures
Name Time Method Factor analysis for medication persistence